TM three-lens brief
Evidence-based stock research on TM. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 18.4pp over 30 days. · Negative free cash flow last quarterly (-$52.14B).
- Underperforming SPY by 18.4pp over 30 days.
- P/E of 10.8 — trading at a value multiple.
- Analyst mean target $255.52 — 33% above current (4 analysts).
- Negative free cash flow last quarterly (-$52.14B).
- Debt-to-equity of 105.3 — balance-sheet-heavy.
TM closed at $192.32 (-1.92%) as of 2026-04-25. Market cap: $250.66B. P/E (trailing) 10.8. Positives: p/E of 10.8 — trading at a value multiple.; analyst mean target $255.52 — 33% above current (4 analysts).. Concerns: underperforming SPY by 18.4pp over 30 days.; negative free cash flow last quarterly (-$52.14B).. Last quarter: Revenue $13.46T, net income $1.26T, free cash flow -$52.14B.
Why three lenses on TM, not one.
A single reasoning model has blind spots it doesn’t know about. We examine TMacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/TM" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath TM brief"></iframe>